BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
|Articles|November 1, 2004
- Volume 0 0
Errata
Advertisement
The article on Home DiagnosticKits in the September 2004 issue ofPharmacy Times should have saidthat the FDA has cleared home testingkits for consumer use.
The article on Fluoroquinolonesin the September issue should havereferred to nalidixic acid as aquinolone.
An error in editing resulted in misinformationin the article, Statins andDiabetes (October 2004). The tableshould have said that there are currently6 statins on the market. Ezetimibe(Zetia) and the combination productezetimibe/simvastatin (Vytorin)should not have been included.
Articles in this issue
almost 22 years ago
Geriatric Pharmacologyalmost 22 years ago
Management of Bacterial Rhinosinusitisalmost 22 years ago
Early RA Treatment Proves Beneficialalmost 22 years ago
Topical Creams Work Temporarilyalmost 22 years ago
Mental Anguish Is Common with Arthritisalmost 22 years ago
Overview of Astrocytomas?The Pharmacist's Perspectivealmost 22 years ago
Scanner Detects Hand Arthritisalmost 22 years ago
OA: All in the Familyalmost 22 years ago
Sheriff Sues Board for Searching His Rx Records Without a Warrantalmost 22 years ago
Restricting the Sale of Cold MedicationsAdvertisement
Related to this article
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
2
What the 2025-2030 Dietary Guidelines Mean for Heart Health
3
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
4
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
5